Literature DB >> 12034092

Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity.

Dexiang Chen1, Ryan L Endres, Cherie A Erickson, Yuh-Fun Maa, Lendon G Payne.   

Abstract

The non-toxic B subunit of cholera toxin (CTB) and E. coli heat-labile toxin mutant proteins with reduced toxicity (LTR72) or no toxicity (LTK63) were used as adjuvants for epidermal powder immunization (EPI) with an influenza vaccine. When administered by EPI, CTB, LTR72 and LTK63 significantly augmented antibody responses to the influenza vaccine and protection against a lethal challenge in a mouse model. The antigen dose could be reduced by 125-fold. These adjuvants were well-tolerated both locally and systemically following EPI. These results suggest that EPI with influenza vaccine and a non-toxic bacterial enterotoxin hold promise for human vaccination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034092     DOI: 10.1016/s0264-410x(02)00215-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae.

Authors:  Ana Paula Mattos Arêas; Maria Leonor Sarno Oliveira; Eliane Namie Miyaji; Luciana Cezar Cerqueira Leite; Paulo Lee Ho
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 3.  Micro-scale devices for transdermal drug delivery.

Authors:  Anubhav Arora; Mark R Prausnitz; Samir Mitragotri
Journal:  Int J Pharm       Date:  2008-08-30       Impact factor: 5.875

Review 4.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 5.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.